June 1, 2023Clarametyx Announces Positive Early Phase 1 Safety Findings on CMTX-101, Immune-Enabling Antibody TherapyRead More May 30, 2023Clarametyx Biosciences Announces Changes to Its Scientific Advisory BoardRead More November 30, 2022Clarametyx Initiates Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101 Against Community-Acquired Bacterial PneumoniaRead More October 5, 2022Clarametyx Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101Read More April 4, 2022CARB-X Awards Clarametyx Biosciences $3.89 Million in Additional Option Funding to Accelerate Anti-biofilm Technology for Life-threatening Bacterial InfectionsRead More December 20, 2021Clarametyx Biosciences Awarded $3.15 Million Grant From NIH to Advance a Broad-spectrum Vaccine Technology for Bacterial InfectionsRead More November 5, 2021New Publication in Cell Implicates a Rare Form of DNA Driving Antimicrobial Resistance in Bacterial BiofilmsRead More September 1, 2021Clarametyx Biosciences Awarded $2.7 Million in Option Funding From CARB-X to Accelerate Novel Technology for Persistent Bacterial InfectionsRead More May 20, 2021Clarametyx Biosciences Expands Board of Directors with Appointment of Financial Executive Michael LaymanRead More
